Preeti Sharma1, Sumanpreet Kaur1, Bhupinder Singh Chadha1, Raminderjit Kaur2, Manpreet Kaur3, Sukhraj Kaur4. 1. Department of Microbiology, Guru Nanak Dev University, Amritsar, Punjab, 143005, India. 2. Department of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab, India. 3. Department of Human Genetics, Guru Nanak Dev University, Amritsar, Punjab, India. 4. Department of Microbiology, Guru Nanak Dev University, Amritsar, Punjab, 143005, India. drsukhrajkaur@gmail.com.
Abstract
BACKGROUND: Increase in the number of infections caused by Gram-negative bacteria in neutropenic cancer patients has prompted the search for novel therapeutic agents having dual anticancer and antimicrobial properties. Bacteriocins are cationic proteins of prokaryotic origin that have emerged as one of the most promising alternative antimicrobial agents with applications as food preservatives and therapeutic agents. Apart from their antimicrobial activities, bacteriocins are also being explored for their anticancer potential. RESULTS: In this study, a broad-spectrum, cell membrane-permeabilizing enterocin with a molecular weight of 65 kDa was purified and characterized from the culture supernatant of vaginal Enterococcus faecium 12a. Enterocin 12a inhibited multidrug-resistant strains of various Gram-negative pathogens such as Salmonella enterica, Shigella flexneri, Vibrio cholerae, Escherichia coli and Gram-positive, Listeria monocytogenes, but had no activities against different strains of gut lactobacilli. The mass spectrometric analysis showed that the enterocin 12a shared partial homology with 4Fe-4S domain-containing redox protein of E. faecalis R712. Further, enterocin 12a selectively inhibited the proliferation of various human cancer cell lines in a dose-dependent manner but not that of normal human peripheral blood mononuclear cells. Enterocin 12a-treated cancer cells showed apoptosis-like morphological changes. CONCLUSION: Enterocin 12a is a novel bacteriocin that has anticancer properties against human cell lines and negligible activity towards non-malignant cells. Therefore, it should be further evaluated for its anticancer potential in animal models.
BACKGROUND: Increase in the number of infections caused by Gram-negative bacteria in neutropenic cancerpatients has prompted the search for novel therapeutic agents having dual anticancer and antimicrobial properties. Bacteriocins are cationic proteins of prokaryotic origin that have emerged as one of the most promising alternative antimicrobial agents with applications as food preservatives and therapeutic agents. Apart from their antimicrobial activities, bacteriocins are also being explored for their anticancer potential. RESULTS: In this study, a broad-spectrum, cell membrane-permeabilizing enterocin with a molecular weight of 65 kDa was purified and characterized from the culture supernatant of vaginal Enterococcus faecium12a. Enterocin 12a inhibited multidrug-resistant strains of various Gram-negative pathogens such as Salmonella enterica, Shigella flexneri, Vibrio cholerae, Escherichia coli and Gram-positive, Listeria monocytogenes, but had no activities against different strains of gut lactobacilli. The mass spectrometric analysis showed that the enterocin 12a shared partial homology with 4Fe-4S domain-containing redox protein of E. faecalis R712. Further, enterocin 12a selectively inhibited the proliferation of various humancancer cell lines in a dose-dependent manner but not that of normal human peripheral blood mononuclear cells. Enterocin 12a-treated cancer cells showed apoptosis-like morphological changes. CONCLUSION:Enterocin 12a is a novel bacteriocin that has anticancer properties against human cell lines and negligible activity towards non-malignant cells. Therefore, it should be further evaluated for its anticancer potential in animal models.
Authors: Veronica L Cavera; Timothy D Arthur; Dimitri Kashtanov; Michael L Chikindas Journal: Int J Antimicrob Agents Date: 2015-08-22 Impact factor: 5.283
Authors: Pilar Casaus; Trine Nilsen; Luis M Cintas; Ingolf F Nes; Pablo E Hernández; Helge Holo Journal: Microbiology (Reading) Date: 1997-07 Impact factor: 2.777
Authors: Ismail M M Othman; Zahra M Alamshany; Nada Y Tashkandi; Mohamed A M Gad-Elkareem; Somaia S Abd El-Karim; Eman S Nossier Journal: RSC Adv Date: 2021-12-22 Impact factor: 3.361
Authors: Eman M Mohi El-Deen; Manal M Anwar; Amina A Abd El-Gwaad; Eman A Karam; Mohamed K El-Ashrey; Rafika R Kassab Journal: Molecules Date: 2022-01-26 Impact factor: 4.411
Authors: Dominika Pindjakova; Eliska Pilarova; Karel Pauk; Hana Michnova; Jan Hosek; Pratibha Magar; Alois Cizek; Ales Imramovsky; Josef Jampilek Journal: Int J Mol Sci Date: 2022-10-01 Impact factor: 6.208